Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer
J. N. Ingle
Consultant or Advisory Role - Pfizer (U)
J. Ales-Martinez
Research Funding - Pfizer
Other Remuneration - Pfizer
A. Cheung
No relevant relationships to disclose
R. T. Chlebowski
No relevant relationships to disclose
J. Wactawski-Wende
Research Funding - Pfizer
A. McTiernan
Consultant or Advisory Role - Novartis; Proctor and Gamble
Stock Ownership - Merck
J. Robbins
No relevant relationships to disclose
K. Johnson
Research Funding - Pfizer
L. Martin
No relevant relationships to disclose
E. Winquist
No relevant relationships to disclose
G. Sarto
No relevant relationships to disclose
J. E. Garber
No relevant relationships to disclose
C. J. Fabian
No relevant relationships to disclose
P. Pujol
No relevant relationships to disclose
E. Maunsell
No relevant relationships to disclose
P. Farmer
No relevant relationships to disclose
K. A. Gelmon
Consultant or Advisory Role - Pfizer
D. Tu
No relevant relationships to disclose
H. Richardson
Research Funding - Pfizer